SG11202108695QA - Method of improving sleep - Google Patents

Method of improving sleep

Info

Publication number
SG11202108695QA
SG11202108695QA SG11202108695QA SG11202108695QA SG11202108695QA SG 11202108695Q A SG11202108695Q A SG 11202108695QA SG 11202108695Q A SG11202108695Q A SG 11202108695QA SG 11202108695Q A SG11202108695Q A SG 11202108695QA SG 11202108695Q A SG11202108695Q A SG 11202108695QA
Authority
SG
Singapore
Prior art keywords
improving sleep
sleep
improving
Prior art date
Application number
SG11202108695QA
Other languages
English (en)
Inventor
Mihael Polymeropoulos
Sandra Smieszek
Original Assignee
Vanda Pharmaceuticals Inc
Mihael Polymeropoulos
Sandra Smieszek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc, Mihael Polymeropoulos, Sandra Smieszek filed Critical Vanda Pharmaceuticals Inc
Publication of SG11202108695QA publication Critical patent/SG11202108695QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Materials For Photolithography (AREA)
SG11202108695QA 2019-02-13 2020-02-13 Method of improving sleep SG11202108695QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805057P 2019-02-13 2019-02-13
PCT/US2020/018082 WO2020168056A1 (en) 2019-02-13 2020-02-13 Method of improving sleep

Publications (1)

Publication Number Publication Date
SG11202108695QA true SG11202108695QA (en) 2021-09-29

Family

ID=69811911

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108695QA SG11202108695QA (en) 2019-02-13 2020-02-13 Method of improving sleep

Country Status (13)

Country Link
US (2) US11458116B2 (ja)
EP (2) EP4186502A1 (ja)
JP (2) JP7139534B2 (ja)
KR (3) KR102425655B1 (ja)
CN (1) CN113993516A (ja)
AU (1) AU2020221347B2 (ja)
BR (1) BR112021015869A2 (ja)
CA (1) CA3129833C (ja)
ES (1) ES2945635T3 (ja)
MX (1) MX2021009616A (ja)
SG (1) SG11202108695QA (ja)
WO (1) WO2020168056A1 (ja)
ZA (1) ZA202106233B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3229930A1 (en) * 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666293C (en) * 2006-05-22 2017-01-10 Vanda Pharmaceuticals, Inc. Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders
ES2648987T3 (es) * 2012-05-18 2018-01-09 Vanda Pharmaceuticals Inc. Metabolitos de (1R-trans)-N-[[2-(2,3-dihidro-4-benzofuranil)ciclopropil]metil]propanamida
CN105142630A (zh) * 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗

Also Published As

Publication number Publication date
WO2020168056A1 (en) 2020-08-20
JP7139534B2 (ja) 2022-09-20
BR112021015869A2 (pt) 2021-10-05
KR20210137045A (ko) 2021-11-17
JP2022174187A (ja) 2022-11-22
EP3923929A1 (en) 2021-12-22
MX2021009616A (es) 2022-01-31
AU2020221347A1 (en) 2021-09-16
ZA202106233B (en) 2023-03-29
US20220040140A1 (en) 2022-02-10
ES2945635T3 (es) 2023-07-05
CA3129833C (en) 2023-01-17
JP7324917B2 (ja) 2023-08-10
US11458116B2 (en) 2022-10-04
EP4186502A1 (en) 2023-05-31
KR20220108201A (ko) 2022-08-02
JP2022516578A (ja) 2022-02-28
KR102425655B1 (ko) 2022-07-27
KR20240058981A (ko) 2024-05-07
US20220387374A1 (en) 2022-12-08
EP3923929B1 (en) 2023-04-05
CA3129833A1 (en) 2020-08-20
AU2020221347B2 (en) 2022-08-25
CN113993516A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
EP3849410A4 (en) SLEEP ENHANCEMENT SYSTEM AND METHOD
EP3684342C0 (en) TREATMENT PROCEDURES
GB201706406D0 (en) Method of treatment
IL285546A (en) Compounds and methods for reducing expression of kcnt1
IL284374A (en) Methods for the production of Ozetakinumab
GB201815588D0 (en) Method of treatment
GB201804594D0 (en) Bonegraft substituteand method of manufacture
GB201802839D0 (en) Method of manufacture
IL289032A (en) A method to reduce side effects of interferon
PL3755681T3 (pl) Sposób wytwarzania 4-boronofenyloalaniny
ZA202106233B (en) Method of improving sleep
GB201909693D0 (en) Computer-implemented method
IL287250A (en) Method of treatment
ZA202105635B (en) Upper and method for the manufacture of an upper
IL286099A (en) Methods of treating the disease using levoketoconazole
SG11202105877YA (en) Method of treatment
GB201907305D0 (en) Treatment of conditions
HUE049463T2 (hu) Eljárás kavicsok kezelésére
PT3527111T (pt) Método e sistema para melhorar a qualidade do sono e colchão que compreende o referido sistema
IL290983A (en) Treatment methods
GB201912103D0 (en) Method of haplotyping
GB201918853D0 (en) Methods of treatment
IL288949A (en) Lamburexant for the treatment of sleep problems
GB201900942D0 (en) Methods of treatment
GB201820236D0 (en) Method of treatment